Press release
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery
About this update from Incyte Corporation
[{"type":"text","content":"\nCollaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies\n\n\n WILMINGTON, Del. & CINCINNATI--(BUSINESS WIRE)--\nIncyte (NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, with Enable’s enFuse® On-Body Delivery System.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027161257/en/\nUnder the terms of the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and myelofibrosis (MF), with the potential to expand to additional assets and indications. Incyte will pay Enable an upfront technology access fee, potential R&D milestones, commercial milestones and a transfer price for clinical and commercial supply of enFuse devices.\n\n\n“At Incyte, we are continually seeking new ways to enhance care and improve the overall treatment pathway for patients,” said Bill Meury, President and Chief Executive Officer, Incyte. “We’re looking forward to partnering with Enable and combining our expertise to make advanced treatments more accessible and less burdensome for patients, while maintaining the high standards of safety and efficacy patients and providers expect.”\n\n\nIncyte is a leader in myeloproliferative neoplasms (MPNs), a group of rare blood cancers including ET and MF, advancing the development of transformative, targeted and disease modifying options for patients across the MPN disease spectrum. INCA033989 is a first-in-class, investigational therapy for patients with calreticulin mutations (mutCALR) – the second most common oncogenic driver of MPNs.\n\n\nThe enFuse system is designed to deliver large volumes of small molecule and biologic medications subcutaneously, allowing patients to receive their needed treatment in a simple injection under the skin, instead of intravenously. Designed to provide a simple, discreet and comfortable patient experience, the enFuse technology enables flexible site-of-care options, including at-home self-...